Fig. 3: Impact of CYP2C19 in clopidogrel-related MACE.
From: Clinical impact of pharmacogenetic risk variants in a large chinese cohort
Forest plot of the MACE risk in clopidogrel users with different CYP2C19 phenotypes: (a) people who carried at least one CYP2C19 LoF alleles vs non-carriers, (b) CYP2C19 IM vs NM, and (c) CYP2C19 PM vs NM. The case number, OR, 95% CI, and P value were listed in the table. The ORs and 95% CIs were estimated using logistic regression adjusting for covariates (two-sided test). Data points represent odds ratios; error bars represent 95% confidence intervals. Significant associations are shown in red. CI = confident interval; CV_death = cardiovascular death; HF = heart failure; IM = intermediate metabolizer; LoF = loss-of-function; MACE = major adverse cardiovascular events; MI = myocardial infarction; NM = normal metabolizer; OR = odds ratio; PM = poor metabolizer; TLR = target lesion revascularization; UA = unstable angina.
